Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma
Clicks: 1
ID: 314573
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #110 of 126 articles by views in journal of neuro-oncology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 126 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based disparity in meningioma. Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera. Although the absolute risk of meningioma remains small, exposure to DMPA increases the risk of meningioma by 1.5- to 5.5-fold. DMPA-associated meningiomas are clinically significant, as the risk of craniotomy for tumor resection, not just the risk of tumor diagnosis, is elevated after DMPA exposure. These data suggest that DMPA should be avoided in individuals with a history of meningioma when alternatives are available. The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma.
| Reference Key |
openalex_W7161935831
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Brooke C Braman, Martha A. Cady, Allison A Merz-Herrala, Alon Witztum, Zora Arum, Scarlett Lin Gomez, Ramin A Morshed, Javier E Villanueva-Meyer, Nancy Ann Oberheim Bush, Susan M Chang, Jennifer Kerns, David R Raleigh |
| Journal | journal of neuro-oncology |
| Year | 2026 |
| DOI |
10.1093/neuonc/noag115
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.